Get 20% lifetime commission for referring investors to digrin.com
here.
Inhibikase Therapeutics, Inc. ( IKT) - Key Metrics
IKT Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.11 | -$0.07 | -$0.07 |
| 2026Q1 | $0 | -$0.10 | -$0.07 | -$0.07 |
| 2025Q4 | $0 | -$0.14 | -$0.08 | -$0.08 |
| 2025Q3 | $0 | -$0.13 | -$0.12 | -$0.12 |
| 2025Q2 | $0 | -$0.11 | -$0.06 | -$0.06 |
IKT Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -4.61 |
| 2026Q1 | 0% | -4.42 |
| 2025Q4 | 0% | -3.66 |
| 2025Q3 | 0% | -3.12 |
| 2025Q2 | 0% | -4.43 |
IKT
Price: $2.36
52 week price:
Earnings Per Share: -0.44 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 146895
Market Capitalization: 336.3 million